Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

3selected

Field	ASPIRIN Haematology · Haematology · Level 2	TICAGRELOR Haematology · Haematology · Level 2	ABCIXIMAB Haematology · Haematology · Level 3
Mechanism of action	Non-specific Irreversible platelet cyclooxygenase inhibitor (COX-1 and 2) via acetylation of serine residues → ↓formation PG precursors. - Inhibits formation of thromboxane (TXA) → inhibit aggregation - At higher doses prostacyclin (PFI2) synthesis also inhibited → vasoconstriction (but endothelium can regenerate COX)	Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Similar mechanism as tirofiban but monoclonal antibody
Absorption	- PO. BA. 50%. - 300mg Loading. 100mg maint.	BA=40%	—
Protein binding	85% protein binding, pKa 3	—	—
Volume of distribution	Vd 10L	—	—
Metabolism	- Converted to salicylic acid in GI mucosa and liver - Hepatic conjugation (saturable)	Metabolized by CYP3A4	Platelet function typically returns to normal 24-48 hours after infusion ceases
Excretion	- Renal as salicylate	—	Platelet function typically returns to normal 24-48 hours after infusion ceases
Half-life	- T1/2b 15~20 mins when first order - Dur: 4-6 hrs. (Effect on platelet aggregation will last life of current cohort of platelets (7-10 days)	—	—
Adverse Effects Toxicity	Bleeding Bronchospasm, Renal toxicity Reye’s Syndrome, GI ulceration Caution with other anticoagulants	—	Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction
Class Group	Antiplatelet	Antiplatelet	Antiplatelet
Introduction	COX inhibitor	ADP Receptor Antagonist - Thienopyridine	GP IIb/IIIA Inhibitor
Legacy Cicm Level	Level 1	Level 3	Level 3
Main Action	Platelet inhibition	Platelet inhibition	Platelet inhibition